EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Clinical implications of loss of interruption variants for diagnosis, genetic counselling, and clinical trials in Huntington's disease

Hailey Findlay Black iD, Jessica Levesley iD, Chris Kay iD, Stephanie Bortnick, Kyla Javier iD, Michael R Hayden iD

Journal of Huntington's Disease · 2026

DOI: 10.1177/18796397261443135 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Huntington's Disease, 2026. Verfasst von Hailey Findlay Black und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada. Hauptthemen laut MEDLINE: Huntington Disease, Genetic Counseling, Huntingtin Protein, Clinical Trials as Topic. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: James Family, Canadian Institutes of Health Research, BC Children's Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Age of onset in Huntington disease (HD) is influenced by cis- acting genetic variants, particularly the loss of interrupting codons in the HTT CAG and CCG repeats (CAG-CCG LOI variant). The CAG-CCG LOI variant is not detectable by current diagnostic assays, leading to underestimation of CAG repeat length, misdiagnosis, and inaccurate prediction of risk of symptom onset in the reduced penetrance range. In clinical trials, unidentified CAG-CCG LOI variants may affect interpretation of results, particularly for small trials. Accurate ascertainment and reporting of the CAG-CCG LOI genotype therefore has important implications for HD diagnosis, genetic counselling, and clinical trial design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Huntington DiseaseGenetic CounselingHuntingtin ProteinClinical Trials as TopicTrinucleotide RepeatsHumansGenetic VariationPenetrance

Stichwörter der Autor:innen

Huntington diseaseHuntington's diseaseclinical trialgenetic counsellinggenetic modifiergenetic testinggenetic variantintermediate alleleloss of interruptionreduced penetrance

Substanzen

Huntingtin ProteinHTT protein, human

Autor:innen und Institutionen

  • Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada.

ORCID-Profile: Hailey Findlay Black, Jessica Levesley, Chris Kay, Kyla Javier, Michael R Hayden

Förderung

  • James Family
  • Canadian Institutes of Health Research
  • BC Children's Hospital

Zitieren

APA

Findlay Black, H., Levesley, J., Kay, C., Bortnick, S., Javier, K., & Hayden, M. R. (2026). Clinical implications of loss of interruption variants for diagnosis, genetic counselling, and clinical trials in Huntington's disease. Journal of Huntington's Disease. https://doi.org/10.1177/18796397261443135

Vancouver

Findlay Black H, Levesley J, Kay C, Bortnick S, Javier K, Hayden MR. Clinical implications of loss of interruption variants for diagnosis, genetic counselling, and clinical trials in Huntington's disease. Journal of Huntington's Disease. 2026. doi:10.1177/18796397261443135

BibTeX
@article{FindlayBlack2026,
  author = {Findlay Black, Hailey and Levesley, Jessica and Kay, Chris and Bortnick, Stephanie and Javier, Kyla and Hayden, Michael R},
  title = {Clinical implications of loss of interruption variants for diagnosis, genetic counselling, and clinical trials in Huntington's disease},
  journal = {Journal of Huntington's Disease},
  year = {2026},
  doi = {10.1177/18796397261443135}
}
Kostenlos starten →